Effects of intracellular Ca2+ chelating compounds on inward currents caused by Ca2+ release from sarcoplasmic reticulum in guinea-pig atrial myocytes.
Ca2+ release from the sarcoplasmic reticulum (SR) of mammalian cardiac myocytes occurring either due to activation by a depolarization or the resulting transmembrane Ca2+ current (ICa), or spontaneously due to Ca2+ overload has been shown to cause inward current(s) at negative membrane potentials. In this study, the effects of different intracellular Ca2+ chelating compounds on ICa-evoked or spontaneous Ca(2+)-release-dependent inward currents were examined in dialysed atrial myocytes from hearts of adult guinea-pigs by means of whole-cell voltage-clamp. As compared to dialysis with solutions containing only a low concentration of a high affinity ethylene glycol-bis(beta-aminoethylether) N,N,N',N'-tetraacetic acid (EGTA) like chelator (50-200 microM), inward membrane currents (at -50 mV) due to evoked Ca2+ release, spontaneous Ca2+ release or Ca2+ overload following long-lasting depolarizations to very positive membrane potentials are prolonged if tne dialysing fluid contains a high concentration of a low affinity Ca2+ chelating compound such as citrate or free adenosine 5'-triphosphate (ATP). Without such a non-saturable Ca2+ chelator in the dialysing fluid, Ca(2+)-release-dependent inward currents are often oscillatory and show an irregular amplitude. With a low affinity chelator in a non-saturable concentration, discrete inward currents with constant properties can be recorded. We conclude that the variability in Ca(2+)-release-dependent inward current seen in single cells arises from spatial inhomogeneities of intracellular Ca2+ concentration ([Ca2+]i) due to localized saturation of endogenous and exogenous high affinity Ca2+ buffers (e.g.). This can be avoided experimentally by addition of a non-saturable buffer to the intracellular solution.(ABSTRACT TRUNCATED AT 250 WORDS)
Lipp
P
P
Department of Cell Physiology, Ruhr-University, Bochum, Federal Republic of Germany.
Pott
L
L
D000818:Animals; D002118:Calcium / Q000378:metabolism / Q000502:physiology*; D002352:Carrier Proteins / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology*; D002951:Citrates / Q000494:pharmacology; D019343:Citric Acid; D003956:Dialysis; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D004594:Electrophysiology; D006168:Guinea Pigs; D006325:Heart Atria; D007425:Intracellular Membranes / Q000378:metabolism; D009206:Myocardium / Q000166:cytology / Q000378:metabolism*; D012519:Sarcoplasmic Reticulum / Q000378:metabolism*; D019831:Sodium-Calcium Exchanger
D002352:Carrier Proteins; D002614:Chelating Agents; D002951:Citrates; D019831:Sodium-Calcium Exchanger; D019343:Citric Acid; D004533:Egtazic Acid; C025603:1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; D002118:Calcium